晚期食管癌患者外周血ERCC1基因多态性与顺铂化疗疗效相关性研究

Clinical outcome of advanced esophageal cancer treated with cisplatin influenced by ERCC1 gene polymorphism in peripheral blood

目的:研究ERCC1C8092A和C1900-7T、GSTP1al05G基因多态与中国晚期食管癌对顺铂(DDP)一线化疗的关系。方法:107例晚期食管癌患者以DDP和5-氟尿嘧啶(5-FU)方案化疗,最终98例患者按要求完成并进行临床疗效评价。检测上述基因位点多态性,分析基因多态性与缓解率、无进展生存时间之间的关系。结果:ERCC1-C8092AA/C或A/A型患者缓解率高于C/C型患者(51.7%vs29.0%,P=0.036),患者无进展生存时间长于C/C型患者(7.5个月vs4.5个月,P<0.0001);其他位点基因多态性与缓解率和无进展生存时间无显著相关性。结论:ERCC1C8092A基因多态性可能与晚期食管癌患者对DDP化疗疗效和无进展生存时间相关。

OBJECTIVE：To investigate the relationship between genetic polymorphisms of ERCC1 C8092A,C19007T and GSTP1 A105G and response to cisplatin chemotherapy of the advanced esophageal cancer.METHODS：Totally 107 patients with advanced esophageal cancer were treated with cisplatin/5-fluorouracil chemotherapy,and 98 of which were eligible for analysis.Genetic polymorphisms examined herein included those in the genes coding ERCC1 and GSTP1.The relationships between genetic polymorphisms and clinical outcome were analyzed.RESULTS：The patients with ERCC1-C8092A A/C or A/A genotype had a higher response rate than the patients with C/C （51.7% vs 29.0%,P=0.036）,and longer PFS （7.5 months vs 4.5 months,P0.000 1）.There was no significant relationship among the response rate and PFS and other genetic polymorphisms.CONCLUSION：The research suggests that the ERCC1 C8092A genetic polymorphisms may be related to the therapeutic responses to cisplatin chemotherapy and PFS in advanced esophageal cancer.